

Supplemental information

Germline variants in tumor suppressor *FBXW7*

lead to impaired ubiquitination

and a neurodevelopmental syndrome

Sarah E.M. Stephenson, Gregory Costain, Laura E.R. Blok, Michael A. Silk, Thanh Binh Nguyen, Xiaomin Dong, Dana E. Alhuzaimi, James J. Dowling, Susan Walker, Kimberly Amburgey, Robin Z. Hayeems, Lance H. Rodan, Marc A. Schwartz, Jonathan Picker, Sally A. Lynch, Aditi Gupta, Kristen J. Rasmussen, Lisa A. Schimmenti, Eric W. Klee, Zhiyv Niu, Katherine E. Agre, Ilana Chilton, Wendy K. Chung, Anya Revah-Politi, P.Y. Billie Au, Christopher Griffith, Melissa Racobaldo, Annick Raas-Rothschild, Bruria Ben Zeev, Ortal Barel, Sebastien Moutton, Fanny Morice-Picard, Virginie Carmignac, Jenny Cornaton, Nathalie Marle, Orrin Devinsky, Chandler Stimach, Stephanie Burns Wechsler, Bryan E. Hainline, Katie Sapp, Marjolaine Willems, Ange-line Bruel, Kerith-Rae Dias, Carey-Anne Evans, Tony Roscioli, Rani Sachdev, Suzanna E.L. Temple, Ying Zhu, Joshua J. Baker, Ingrid E. Scheffer, Fiona J. Gardiner, Amy L. Schneider, Alison M. Muir, Heather C. Mefford, Amy Crunk, Elizabeth M. Heise, Francisca Millan, Kristin G. Monaghan, Richard Person, Lindsay Rhodes, Sarah Richards, Ingrid M. Wentzensen, Benjamin Cogné, Bertrand Isidor, Mathilde Nizon, Marie Vincent, Thomas Besnard, Amelie Piton, Carlo Marcelis, Kohji Kato, Norihisa Koyama, Tomoo Ogi, Elaine Suk-Ying Goh, Christopher Richmond, David J. Amor, Jessica O. Boyce, Angela T. Morgan, Michael S. Hildebrand, Antony Kaspi, Melanie Bahlo, Rún Friðriksdóttir, Hildigunnur Katrínardóttir, Patrick Sulem, Kári Stefánsson, Hans Tómas Björnsson, Simone Mandelstam, Manuela Morleo, Milena Mariani, TUDP Study Group, Marcello Scala, Andrea Accogli, Annalaura Torella, Valeria Capra, Mathew Wallis, Sandra Jansen, Quinten Waisfisz, Hugoline de Haan, Simon Sadedin, Broad Center for Mendelian Genomics, Sze Chern Lim, Susan M. White, David B. Ascher, Annette Schenck, Paul J. Lockhart, John Christodoulou, and Tiong Yang Tan

Acknowledgements

UDP-Vic acknowledges financial support from the Murdoch Children's Research Institute and the Harbig Foundation. The Rare Disease Flagship acknowledges financial support from the Royal Children's Hospital Foundation, the Murdoch Children's Research Institute, and the Harbig Foundation. The research conducted at the Murdoch Children's Research Institute and Baker Heart and Diabetes Institute was supported by the Victorian Government's Operational Infrastructure Support Program. Sequencing and analysis of Individual 1 were provided by the Broad Institute of MIT and Harvard Center for Mendelian Genomics (Broad CMG) and was funded by the National Human Genome Research Institute, the National Eye Institute, and the National Heart, Lung and Blood Institute grant UM1 HG008900 to Daniel MacArthur and Heidi Rehm.

The research pertaining to Individual 18 was supported by Telethon Undiagnosed Diseases Program (TUDP, GSP15001).

Sequencing of Individual 31 was funded by CREGEMES and Sanger validated by Claire Feger.

The research conducted at The Hospital for Sick Children (Canada) was supported in part by the Norm Saunders Complex Care Initiative, SickKids Centre for Genetic Medicine, and University of Toronto McLaughlin Centre.

The Chair in Genomic Medicine awarded to J.C. is generously supported by The Royal Children's Hospital Foundation.

This work was in part supported by a grant awarded under the Australian National Health & Medical Research Council (NHMRC) Centre for Research Excellence Scheme

(APP1117394) to L.E.R.B., A.S., T.R., K-R.D., C-A.E. and by a personal Vici grant (09150181910022) from The Netherlands Organization for Scientific Research (NWO) to A.S.

Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under Award Number T32CA136432. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

D.B.A, T.B.N. and M.S. were supported by an Investigator Grant from the National Health and Medical Research Council (NHMRC) of Australia (GNT1174405).

This publication was supported by the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant Number UL1TR001873. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

M.S.H., M.B. and A.T.M. are funded by a National Health and Medical Research Council (NHMRC) Centre of Research Excellence Grant (1116976). M.B. was funded by an NHMRC Senior Research Fellowship (ID:1102971).




Figure S1: Distribution of neurodevelopment variants within FBXW7 relative to known COSMIC and gnomAD variants. (A) Location of patient-ascertained missense variants (red) and stop-gained and frameshift variants (purple). (B) Distribution of 1481 (440 unique) Catalogue Of Somatic Mutations In Cancer (COSMIC) somatic mutations (red) in FBXW7, where bubble size corresponds to the number of observations.

(C) Distribution of 280 missense variants (277 unique) in FBXW7 gnomAD v2.1 (140k exomes and genomes) variants with bubble size corresponding to the number of observations. (D) Comparison of structural predictors of neurodevelopmental disease variants to gnomAD variants. The gnomAD dataset was filtered to only those within the FBXW7 experimental structure, which includes residues 263 - 706, giving 78 variants only. Of these, the majority are very rare in the population (Allele Count: No. observations – 1:55, 2:14, 3:5, 6:2, 7:1, 12:1). Protein stability, determined using mutation Cutoff Scanning Matrix (mCSM), predicted the majority of gnomAD variants to also have a destabilizing effect, and to be similarly distributed to the patient cohort variants. Binding affinity, determined using mCSM-Protein–protein interactions (PPI) 1&2 ($\Delta\Delta G$), suggests that gnomAD variants have a much smaller effect on binding affinity compared to the patient variants. Additionally, the gnomAD variants are dispersed throughout the structure and are, on average, further from the predicted interface with CYCLIN E1. See Table S3 for individual variant data.




Figure S2: Change in interaction with CYCLIN E1 predicted by each variant

Zoom-in of the interaction of wild-type/variant residues of FBXW7 and its surrounding residues. The variant residues are overlaid on wild-type residues to identify the changes in interaction when variant occurs. FBXW7 is shown in brown ribbon, while CYCLIN E1 is shown in a light gray surface. All wild-type, and variant residues are shown in magenta and cyan sticks, respectively, while surrounding residues of FBXW7 and TPPXS motif of CYCLIN E1 are shown in brown and green sticks. The Oxygen and Nitrogen atoms are in red, and blue, respectively. Hydrogen bond interactions are shown in the red dash lines. Variants that reoccur are indicated by the bold title.




Figure S4: Knockdown of ago in Drosophila neurons induced by the elav^(l)-Gal4 driver causes faster decline of jump response due to fatigue

The knockdown of ago leads to a lower mTTC compared to the controls. Increasing the inter-trial interval in the fatigue assay, preventing habituation from being formed, demonstrates that this lower TTC is not due to improved habituation but due to motor fatigue. Precise genotypes tested in the fatigue assay: elav^(l) C155-Gal4, GMR-w1R /Y; +/+; +/+ of genetic background control in gray and elav^(l) C155-Gal4, GMR-w1R /Y; +/+; UAS-RNAi-2/+ of RNAi-2 knockdown in blue. N_{control} = 42, N_{RNAi-2} = 48, mTTC_{control} = 44.53, mTTC_{RNAi-2} = 25.85, p = 1.35E-5. Statistical significance was assessed by a linear model regression analysis on the log transformed mTTC values, * P < 0.05, ** P < 0.01, *** P < 0.001.




Figure S5: Relative expression of ago in Drosophila knockdown lines

Quantitative RT-PCR was performed on wandering L3 larva from RNAi-1 and RNAi-2 lines crossed to the ubiquitous Act-Gal4/TM3 Sb Tb driver to determine the level of *ago* expression using exon spanning primers to *ago* and β' COP. Error bars represent standard deviation.

Table S1: Analysis of FBXW7 neurodevelopmental syndrome variants

Individual	Inheritance	gDNA (Chr4; GRCh37)	Exon	cDNA	Protein	Occurs within WD40 domain	gnomAD - germline variants		COSMIC - somatic variants		CADD		FATHMM		GERP++ RS		MPC		MTR		MutationAssessor			PROVEAN			Polyphen2			SIFT			VEST4				
							Same variant	Alternative change at same amino acid residue	Same variant	Alternative change at same amino acid residue	score	rank score	score	rank score	predicted consequence	score	rank score	score	rank score	score	rank score	predicted consequence	score	rank score	predicted consequence	score	rank score	predicted consequence	score	rank score	predicted consequence	score	rank score				
1	de novo	g.153249446_153249447del	11	c.1331_1332del	p.(Lys444Serfs*27)	NMD predicted	Absent	3 LoF variants upstream	Absent	p.(Lys444Glyfs*55), p.(Lys444Argfs*32), p.(Lys444Ilefs*2), more than 10 NMD predicted variants	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
2	de novo	g.153249446dup	11	c.1332dup	p.(Val445Serfs*27)	NMD predicted	Absent	3 LoF variants upstream	Absent	p.(Val445Cysfs*53), p.(Val445Aspfs*27), more than 10 NMD predicted variants	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
3	familial	g.153245477_153245478del	13	c.1713_1714del	p.(Asn572Leufs*32)	Truncation predicted	Absent	3 LoF variants upstream	Absent	More than 10 NMD predicted variants	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
4																																					
5																																					
6																																					
7	de novo	g.153244218T>A	14	c.1939A>T	p.(Lys647*)	Truncation predicted	Absent	3 LoF variants upstream	Absent	p.(Lys647Asnfs*5) in stomach carcinoma, more than 10 NMD predicted variants	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
8	de novo	g.153250822A>T	intron 10	c.1236+2T>A	p.?	N/A	Absent	Alternative change at same nucleotide: Absent	Present (stomach carcinoma)	Alternative change at same nucleotide: c.1236+2T>C (large intestine adenocarcinoma)	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
9	de novo	arr[GRCh37]4q31.3(152720434_153661857)x1 dn	N/A	N/A	Entire gene deleted	N/A	N/A	N/A	N/A	N/A	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
10	de novo	arr[GRCh37]4q31.3q32.1(152854578_156285170)x1 dn,4q32.1q34.1(161464002_175617314)x3 dn,4q34.1q34.3(175858796_179802170)x3 dn	N/A	N/A	Entire gene deleted	N/A	N/A	N/A	N/A	N/A	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
11	de novo	g.153249531G>A	11	c.1247C>T	p.(Thr416Ile)	Yes	Absent	Absent	Absent	Absent	4.22	0.86	0.13	0.61	T	5.90	0.95	2.78	0.99	0.56	0.97	1.37	0.34	L	-5.66	0.87	D	1.00	0.92	D	0.05	0.56	D	0.78	0.80		
12	familial	g.153249532T>C	11	c.1246A>G	p.(Thr416Ala)	Yes	Absent	Absent	Absent	Absent	4.08	0.81	0.04	0.62	T	5.90	0.95	2.40	0.97	0.56	0.97	1.71	0.44	L	-4.80	0.81	D	0.98	0.81	D	0.02	0.59	D	0.80	0.81		
13	de novo	g.153249519T>A	11	c.1259A>A	p.(His420Leu)	Yes	Absent	Absent	Absent	Multiple	4.13	0.83	-1.50	0.81	D	5.90	0.95	3.08	0.99	0.87	0.59	4.72	1.00	H	-10.92	0.99	D	1.00	0.97	D	0.00	0.91	D	0.94	0.95		
14	de novo	g.153249511C>T	11	c.1267G>A	p.(Gly423Arg)	Yes	Absent	Absent	Present (multiple tissue types)	Multiple	4.35	0.89	0.16	0.61	T	5.90	0.95	3.01	0.99	0.67	0.92	1.21	0.30	L	-7.94	0.96	D	1.00	0.97	D	0.00	0.91	D	0.94	0.96		
15																																					
16	de novo	g.153249457G>C	11	c.1321C>G	p.(Arg441Gly)	Yes	Absent	Absent	Present (lung carcinoma, rhabdomyosarcoma)	Multiple	3.72	0.70	2.02	0.21	T	4.08	0.47	3.14	0.99	0.55	0.97	0.42	0.13	N	-6.83	0.93	D	0.99	0.80	D	0.03	0.91	D	0.84	0.86		
17	de novo	g.153249394A>G	11	c.1384T>C	p.(Ser462Pro)	Yes	Absent	Absent	Absent	p.(Ser462Tyr), p.(Ser462Phe)	4.33	0.89	0.86	0.74	T	6.05	0.98	2.78	0.99	0.54	0.97	2.65	0.77	M	-4.96	0.82	D	0.93	0.92	D	0.00	0.78	D	0.87	0.89		
18	de novo	g.153249384C>T	11	c.1394G>A	p.(Arg465His)	Yes	Absent	p.(Arg465Cys) (allele balance 45% or lower)	Present (more than 5 tissue types)	Multiple	4.17	0.84	0.97	0.43	T	6.05	0.98	3.08	0.99	0.61	0.95	1.26	0.32	L	-4.96	0.82	D	1.00	0.97	D	0.02	0.91	D	0.78	0.79		
19	de novo (mosaic 14%)	g.153247366C>T	12	c.1436G>A	p.(Arg479Gln)	Yes	Absent	p.(Arg479Gly) (allele balance 25-30%)	Present (more than 5 tissue types)	Multiple	4.17	0.84	1.02	0.41	T	5.72	0.89	2.93	0.99	0.80	0.75	0.84	0.21	L	-3.97	0.74	D	1.00	0.97	D	0.02	0.51	D	0.64	0.65		
20	de novo	g.153247363T>C	12	c.1439A>G	p.(Asp480Gly)	Yes	Absent	Absent	Present (colon adenocarcinoma)	Multiple	4.46	0.91	-2.49	0.89	D	5.72	0.89	3.19	0.99	0.86	0.60	3.93	0.96	H	-6.95	0.93	D	1.00	0.97	D	0.00	0.91	D	0.99	0.99		
21	de novo	g.153247288C>T	12	c.1514G>A	p.(Arg505His)	Yes	Absent	Absent	Present (more than 5 tissue types)	Multiple	4.17	0.85	0.05	0.62	T	4.87	0.63	3.08	0.99	0.55	0.97	1.50	0.38	L	-4.96	0.82	D	1.00	0.97	D	0.01	0.78	D	0.75	0.75		
22	de novo	g.153247171A>C	12	c.1631T>G	p.(Val544Gly)	Yes	Absent	Absent	Present (large intestine adenocarcinoma)	p.(Val544Asp) (mouth squamous cell carcinoma)	4.29	0.88	-0.79	0.74	T	5.72	0.89	3.18	0.99	0.55	0.97	4.32	0.98	H	-6.95	0.93	D	1.00	0.92	D	0.00	0.91	D	0.64	0.66		
23	de novo	g.153245453G>A	13	c.1738C>T	p.(His580Tyr)	Yes	Absent	Absent	Present (large intestine adenocarcinoma)	Multiple	4.09	0.82	-1.49	0.81	T	5.70	0.89	2.95	0.99	0.75	0.84	4.04	0.97	H	-5.96	0.89	D	1.00	0.97	D	0.01	0.56	D	0.89	0.89		
24	de novo	g.153245447A>C	13	c.1744T>G	p.(Ser582Ala)	Yes	Absent	Absent	Absent	Multiple	4.02	0.79	1.00	0.41	T	5.70	0.89	0.97	0.97	0.76	0.83	1.46	0.37	L	-2.70	0.61	D	0.98	0.75	D	0.10	0.59	T	0.66	0.67		
25	de novo (mosaic 23%)	g.153245395G>A	13	c.1796C>T	p.(Ala599Val)	Yes	Absent	p.(Ala599Gly) (allele balance 35-40%)	Absent	Absent	4.29	0.88	0.94	0.44	T	5.45	0.80	2.69	0.99	0.86	0.62	0.86	0.21	L	-3.96	0.74	D	1.00	0.84	D	0.02	0.78	D	0.63	0.64		
26	de novo	g.153244280G>A	14	c.1877C>T	p.(Ala626Val)	Yes	Absent	Absent	Present (large intestine adenocarcinoma)	p.(Ala626Thr), p.(Ala626Pro), p.(Ala626Asp)	4.13	0.83	0.96	0.43	T	5.67	0.88	2.73	0.99	0.63	0.94	1.71	0.44	L	-3.91	0.74	D	1.00	0.91	D	0.00	0.78	D	0.74	0.76		
27	de novo	g.153244237G>T	14	c.1920C>A	p.(Ser640Arg)	Yes	Absent	Absent	Absent	Absent	3.40	0.62	0.97	0.43	T	3.03	0.34	2.87	0.99	0.81	0.72	2.58	0.75	M	-4.91	0.82	D	1.00	0.92	D	0.06	0.60	T	0.87	0.92		
28	de novo	g.153245369T>C	13	c.1822A>G	p.(Ile608Val)	No	Absent	Absent	Absent	Absent	2.43	0.40	0.90	0.45	T	5.45	0.80	1.39	0.85	0.37	0.99	0.18	0.09	N	-0.86	0.23	N	0.05	0.30	B	0.22	0.19	T	0.36	0.41		
29	de novo	g.153244136C>G	14	c.2021G>C	p.(Arg674Pro)	No	Absent	Absent	Absent	p.(Arg674Trp), p.(Arg674Gln)	4.13	0.83	2.21	0.18	T	4.82	0.62	3.35	1.00	0.52	0.98	2.67	0.78	M	-6.83	0.93	D	1.00	0.89	D	0.00	0.78	D	0.81	0.85		
30	de novo	g.153244137G>A	14	c.2020C>T	p.(Arg674Trp)	No	Absent	Absent	Present (glioma, cervix squamous cell carcinoma, atypical meningioma, prostate adenocarcinoma)	p.(Arg674Gln) (colon adenocarcinoma, stomach adenocarcinoma)	3.77	0.71	2.20	0.19	T	1.62	0.23	2.77	0.99	0.52	0.98	2.67	0.78	M	-7.80	0.96	D	1.00	0.92	D	0.00	0.91	D	0.80	0.88		
31																																					
32	de novo	g.153244091C>T	14	c.2066G>A	p.(Arg689Gln)	No	Absent	Absent	Present (more than 5 tissue types)	p.(Arg689Glu), p.(Arg689Trp)	4.14	0.83	2.25	0.18	T	4.82	0.62	2.62	0.98	0.40	0.99	2.70	0.79	M	-3.92	0.73	D	1.00	0.89	D	0.03	0.68	D	0.82	0.87		
33	de novo	g.153244092G>A	14	c.2065C>T	p.(Arg689Trp)	No	Absent	Absent	Present (more than 5 tissue types)	p.(Arg689Glu), p.(Arg689Gln)	4.22	0.86	2.20	0.19	T	5.67	0.88	2.77	0.99	0.40	0.99	2.70	0.79	M	-7.88	0.96	D	1.00	0.97	D	0.03	0.91	D	0.86	0.91		
34																																					
35																																					

Tolerated (T); Deleterious (D); Low (L); Medium (M); High (H); Combined Annotation Dependent Depletion (CADD); Functional Analysis through Hidden Markov Models (FATHMM); Genomic Evolutionary Rate Profiling (GERP) ++ rejected substitutions* (RS) score; missense badness, PolyPhen-2, and constraint (MPC); Missense Tolerance Ratio (MTR); Protein Variation Effect Analyzer (PROVEAN); Polymorphism Phenotyping v2 (PolyPhen-2); Sorting Intolerant From Tolerant (SIFT); Variant Effect Scoring Tool (VEST).

Table S3: HPO terms associated with FBXW7 Neurodevelopmental syndrome

Prenatal history	Thickened nuchal skin fold HP:0000474 Jaundice HP:0000952 Breech presentation HP:0001623 Neonatal hypoglycemia HP:0001998 Hyperechogenic kidneys HP:0004719 Neonatal respiratory distress HP:0002643	Global developmental delay HP:0001263 Intellectual disability, borderline HP:0006889 Anxiety HP:0000739 Poor suck HP:0002033 Motor delay HP:0001270 Specific learning disability HP:0001328 Delayed speech and language development HP:0000750 Speech articulation difficulties HP:0009088 Sleep disturbance HP:0002360 Impulsivity HP:01007710 Short attention span HP:0000736 Autistic behavior HP:0000729 Speech apraxia HP:0011098 Developmental regression HP:0002376 Hair-pulling HP:0012167 Depression HP:0000716	Cardiac problems	Bicuspid aortic valve HP:0001647 Patent ductus arteriosus HP:0001643 Atrial septal defect HP:0001631 Ventricular septal defect HP:0001629 Interrupted aortic arch HP:0011611 Subvalvular aortic stenosis HP:0001682 Abnormal left ventricular function HP:0005162 Secundum atrial septal defect HP:0001684 Persistent left superior vena cava HP:0005301 Patent foramen ovale HP:0001655 Mesocardia HP:0011599	Hematologic problems	Neutropenia HP:0001875 Thrombocytopenia HP:0001873 Normocytic anemia HP:0001897 Iron deficiency anemia HP:0001891 Anemia HP:0001903	Growth	Short stature HP:0004322 Tall stature HP:0000098 Obesity HP:0001513 Macrocephaly HP:0000256 Microcephaly HP:0000252	Hands/feet	Tapered finger HP:0001182 Single transverse palmar crease HP:0000954 Short foot HP:0001773 Pes planus HP:0001763 Overlapping toe HP:0001845 Clinodactyly HP:0030084 Metatarsus adductus HP:0001840 2-3 toe syndactyly HP:0004691 Prominent fingertip pads HP:0001212 Finger swelling HP:0025131 Short 5th finger HP:0009237 Interphalangeal joint contracture of finger HP:0001220 Prominent calcaneus HP:0012428 Abnormality of the 2nd toe HP:0010319
Neurological problems	Hypotonia HP:0001252 Seizure HP:0001250 Progressive spasticity HP:0002191 Unsteady gait HP:0002317 Broad-based gait HP:0002136 Paroxysmal tonic upgaze HP:0033980 Early onset absence seizures HP:0011152 Achilles tendon contracture HP:0001771 Abnormality of coordination HP:0011443 Migraine HP:0002076 Photophobia HP:0000613 Ataxia HP:0001251 Dyskinesia HP:0100660 Stereotypy HP:0000733 Drooling HP:0002307 Atonic seizure HP:0010819	Ophthalmologic problems	Respiratory problems	Obstructive sleep apnea HP:0002870 Snoring HP:0025267 Asthma HP:0002099 Recurrent pneumonia HP:0006532 Recurrent sinusitis HP:0011108 Abnormality of the maxillary sinus HP:0430023 Recurrent upper respiratory tract infections HP:0002788 Bronchitis HP:0012387	Musculoskeletal problems	Sprengel anomaly HP:0000912 Webbed neck HP:0000465 Joint laxity HP:0001388 Short finger HP:0009381 Broad thumb HP:0011304 Increased muscle fatigability HP:0003750 Pectus excavatum HP:0000767 Pectus carinatum HP:0000768 Hemihypertrophy HP:0001528 Scoliosis HP:0002650 Hip dislocation HP:0002827 Hypertonia HP:0001276 Kyphosis HP:0002808 Calcaneovalgus deformity HP:0001848 Genu valgum HP:0002857	Facial features	Broad forehead HP:0000337 Abnormal nasal bridge morphology HP:0000422 Periorbital fullness HP:0000629 Malar flattening HP:0000272 Deeply set eye HP:0000490 Thin vermilion border HP:0000233 Underdeveloped superior crus of antihelix HP:0011246 Preauricular pit HP:0004467 Epicanthus HP:0000286 Thick eyebrow HP:0000574 Synophrys HP:0000664 Large earlobe HP:0009748 Downturned corners of mouth HP:0002714 Prominent forehead HP:0011220 Hypertelorism HP:0000316 Telecanthus HP:0000506 Almond-shaped palpebral fissure HP:0007874 Low-set, posteriorly rotated ears HP:0000368 Prominent metopic ridge HP:0005487 Dolichocephaly HP:0000268 Flat occiput HP:0005469 Wide nasal bridge HP:0000431 Eversion of lateral third of lower eyelids HP:0007655 Thickened helices HP:0000391 Microtia HP:0008551 Micrognathia HP:0000347 Smooth philtrum HP:0000319 Highly arched eyebrow HP:0002553 Myopathic facies HP:0002058 Hypotelorism HP:0000601 Prominent eyelashes HP:0011231 Long palpebral fissure HP:0000637 Downslanted palpebral fissures HP:0000494 Anteverted nares HP:0000463 Overfolded helix HP:0000396 Prominent inferior crus of antihelix HP:0011238 Narrow mouth HP:0000160 Short nose HP:0003196 Prominent nasal tip HP:0005274 Tented upper lip vermilion HP:0010804 Deep philtrum HP:0002002 Scaphocephaly HP:0030799 Prominent occiput HP:0000269 Anteverted ears HP:0040080 Depressed nasal bridge HP:0005280 Low anterior hairline HP:0000294 Thick vermilion border HP:0012471 Incisor macrodontia HP:0011081	Other	Supernumerary nipple HP:0002558 Narrow chest HP:0000774 Umbilical hernia HP:0001537
Brain Imaging	Enlarged cerebellum HP:0012081 Arnold-Chiari type I malformation HP:0007099 Thin corpus callosum HP:0033725 Agenesis of corpus callosum HP:0001274 Abnormal corpus callosum morphology HP:0001273 Punctate periventricular T2 hyperintense foci HP:0030081 Aplasia/Hypoplasia of the cerebellum HP:0007360 Enlarged cisterna magna HP:0002280 Abnormal brainstem morphology HP:0002363 Brain atrophy HP:0012444 Subcortical white matter calcifications HP:0007346 Delayed myelination HP:0012448 Extra-axial cerebrospinal fluid accumulation HP:0012510 Polymicrogyria HP:0002126 Ventriculomegaly HP:0002119 Dilation of Virchow-Robin spaces HP:0012520	Audiology / hearing	Gastrointestinal problems/ feeding difficulties	Feeding difficulties HP:0011968 Nasogastric tube feeding in infancy HP:0011470 Chronic constipation HP:0012450 Polyphagia HP:0002591 Gastroesophageal reflux HP:0002020 Velopharyngeal insufficiency HP:0000220 Constipation HP:0002019 Failure to thrive HP:0001508 Diarrhea HP:0002014	Immunological problems	Decreased circulating antibody level HP:0004313 Recurrent fever HP:0001954				
	Oral / dentition / other ENT problems	Otitis media with effusion HP:0031353 Submucous cleft of soft and hard palate HP:0410031 High palate HP:0000218 Widely spaced teeth HP:0000687 Cleft soft palate HP:0000185 Dental malocclusion HP:0000689 Midface retrusion HP:0011800 Ankyloglossia HP:0010296 Poor suck HP:0002033 Impaired oropharyngeal swallow response HP:0031162 Episodic upper airway obstruction HP:0012271 Short uvula HP:0010812 Anterior open-bite malocclusion HP:0009102 Carious teeth HP:0000670 Laryngeal cleft HP:0008751 Delayed eruption of teeth HP:0000684 Laryngomalacia HP:0001601 Narrow palate HP:0000189 Abnormal ear morphology HP:0031703 Bifid uvula HP:0000193 Nasal speech HP:0001611 Deviated nasal septum HP:0004411	Renal / genitourinary problems	Bilateral cryptorchidism HP:0008689 Multicystic kidney dysplasia HP:0000003 Enlarged kidney HP:0000105 Nocturia HP:0000017 Inguinal hernia HP:0000023 Urinary incontinence HP:0000020 Micropenis HP:0000054 Decreased testicular size HP:0008734 Ventral shortening of foreskin HP:0012435 Abnormal renal corticomedullary differentiation HP:0005932	Skin problems	Acne HP:0001061 Telangiectasia HP:0001009 Blue nevus HP:0100814 Hypertrichosis HP:0000998 Melanocytic nevus HP:0000995 Poliosis HP:0002290 Hypopigmentation of the skin HP:0001010 Distributed along Blaschko lines HP:0025293 Cafe-au-lait spot HP:0000957 Hyperpigmentation of the skin HP:0000953 Nevus flammeus HP:0001052 Capillary hemangioma HP:0005306				

Table S4: Impact of neurodevelopmental syndrome variants on protein stability and interaction with CYCLIN E1.

	mCSM-Stability ($\Delta\Delta G$) - previous structure	mCSM-Stability ($\Delta\Delta G$)	Change in protein stability	Distance to interface (Å)	mCSM-PPI 1&2 ($\Delta\Delta G$)	Change in PPI binding affinity	Δ Charge	Δ Volume	Δ Residue nature
p.(Thr416Ile)	-0.134	-0.179	Decrease	15.1	-0.07	Decrease	0	50.6	Polar -> Hydrophobic
p.(Thr416Ala)		-0.788	Decrease	15.1	-0.134	Decrease	0	-27.5	Polar -> Hydrophobic
p.(His420Leu)		-0.823	Decrease	12.4	-0.469	Decrease	Partial	13.5	Partial charge -> Neutral
p.(Gly423Arg)	-1.031	-0.985	Decrease	7.8	-0.264	Decrease	1	113.3	Neutral -> Basic
p.(Arg441Gly)	-1.258	-1.367	Decrease	2.8	0.179	Increase	-1	-113.3	Basic -> Neutral
p.(Ser462Pro)		0.973	Increase	2.6	-2.449	Decrease	0	23.7	Polar -> Hydrophobic
p.(Arg465His)		-1.834	Decrease	5.1	0.286	Increase	Partial	-20.2	Basic -> Partial charge
p.(Arg479Gln)	-0.625	-1.346	Decrease	3.1	0.054	Increase	-1	-29.6	Basic -> Unchanged
p.(Asp480Gly)	0.327	1.401	Increase	4.5	-1.998	Decrease	1	-51	Acidic -> Neutral
p.(Arg505His)	-2.019	-2.032	Decrease	5.4	-0.038	Neutral	Partial	-20.2	Basic -> Partial charge
p.(Val544Gly)	-3.203	-3.16	Decrease	9.1	-1.114	Decrease	0	-79.9	Hydrophobic -> Hydrophobic
p.(His580Tyr)	-0.414	-0.422	Decrease	9.1	0.311	Increase	Partial	40.4	Partial charge -> Aromatic
p.(Ser582Ala)		0.033	Increase	3.54	-0.422	Decrease	0	-0.4	Polar -> Hydrophobic
p.(Ala599Val)	-0.451	-0.093	Neutral	4	0.265	Increase	0	51.4	Hydrophobic -> Hydrophobic
p.(Ala626Val)		-0.106	Decrease	4.4	0.291	Increase	0	51.4	Hydrophobic -> Hydrophobic
p.(Ser640Arg)	-0.639	-0.586	Decrease	11.1	-0.355	Decrease	1	84.4	Polar -> Basic
p.(Ile608Val)		-2.019	Decrease	22.3	-0.244	Decrease	0	-33.4	Hydrophobic -> Hydrophobic
p.(Arg674Pro)	-0.648	-0.614	Decrease	8.1	-0.321	Decrease	-1	-60.7	Basic -> Neutral
p.(Arg674Trp)	-0.283	-0.157	Decrease	8.1	0.013	Neutral	-1	54.4	Basic -> Aromatic
p.(Arg689Gln)	-0.079	-0.353	Decrease	3.4	-0.54	Decrease	-1	-29.6	Basic -> Neutral
p.(Arg689Trp)		-0.357	Decrease	3.4	-0.437	Decrease	-1	54.4	Basic -> Aromatic

mutation Cutoff Scanning Matrix (mCSM); Protein-protein interactions (PPI)

Table S5: Comparison of the impact of neurodevelopmental syndrome variants and gnomAD variants on protein stability and substrate binding

Variant	Amino acid reference	Amino acid position	Amino acid change	mCSM-Stability ($\Delta\Delta G$)	Distance to interface (Å)	mCSM-PPI 1&2 ($\Delta\Delta G$)	Allele Count	Class	Chromosome	Position	rsID	Reference	Alternate	Source	Protein Consequence	Transcript Consequence
T416A	T	416	A	-0.788	15.1	-0.134	1	clin	4	153247315	-	G	A	This study	p.(Thr416Ile)	c.1247C>T
T416I	T	416	I	-0.179	15.1	-0.07	1	clin	4	153249532	-	T	C	This study	p.(Thr416Ala)	c.1246A>G
H420L	H	420	L	-0.823	12.4	-0.469	1	clin	4	153249519	-	T	A	This study	p.(His420Leu)	c.1259 A>T
G423R	G	423	R	-0.985	7.8	-0.264	2	clin	4	153249511	-	C	T	This study	p.(Gly423Arg)	c.1267G>A
R441G	R	441	G	-1.367	2.8	0.179	1	clin	4	153249457	-	G	C	This study	p.(Arg441Gly)	c.1321C>G
S462P	S	462	P	0.973	2.6	-2.449	1	clin	4	153249394	-	A	G	This study	p.(Ser462Pro)	c.1384T>C
R465H	R	465*	H	-1.834	5.1	0.286	1	clin	4	153249384	-	C	T	This study	p.(Arg465His)	c.1394G>A
R479Q	R	479*	Q	-1.346	3.1	0.054	1	clin	4	153247366	-	C	T	This study	p.(Arg479Gln)	c.1436G>A
D480G	D	480	G	1.401	4.5	-1.998	1	clin	4	153247363	-	T	C	This study	p.(Asp480Gly)	c.1439A>G
R505H	R	505	H	-2.032	5.4	-0.038	1	clin	4	153247288	-	C	T	This study	p.(Arg505His)	c.1514G>A
V544G	V	544	G	-3.16	9.1	-1.114	1	clin	4	153247171	-	A	C	This study	p.(Val544Gly)	c.1631T>G
H580Y	H	580	Y	-0.422	9.1	0.311	1	clin	4	153245453	-	G	A	This study	p.(His580Tyr)	c.1738C>T
A599V	A	599*	V	-0.093	4	0.265	1	clin	4	153245395	-	G	A	This study	p.(Ala599Val)	c.1796C>T
I608V	I	608	V	-2.019	22.3	-0.244	1	clin	4	153245369	-	T	C	This study	p.(Ile608Val)	c.1822A>G
S640R	S	640	R	-0.586	11.1	-0.355	1	clin	4	153244237	-	G	T	This study	p.(Ser640Arg)	c.1920C>A
R674P	R	674	P	-0.614	8.1	-0.321	1	clin	4	153244136	-	C	G	This study	p.(Arg674Pro)	c.2021G>C
R674W	R	674	W	-0.157	8.1	0.013	1	clin	4	153244137	-	G	A	This study	p.(Arg674Trp)	c.2020C>T
R689Q	R	689	Q	-0.353	3.4	-0.54	1	clin	4	153244091	-	C	T	This study	p.(Arg689Gln)	c.2066G>A
R689W	R	689	W	-0.357	3.4	-0.437	2	clin	4	153244092	-	G	A	This study	p.(Arg689Trp)	c.2065C>T
V265I	V	265	I	-1.029	57.368	0.119	1	gnomad	4	153259022	rs1393933844	C	T	gnomAD Genomes	p.Val265Ile	c.793G>A
H267R	H	267	R	-0.581	61.633	-0.111	1	gnomad	4	153259015	rs1172754641	T	C	gnomAD Exomes	p.His267Arg	c.800A>G
V271M	V	271	M	-0.254	64.686	-0.311	1	gnomad	4	153259004	rs764074483	C	T	gnomAD Exomes	p.Val271Met	c.811G>A
K286E	K	286	E	-0.462	60.444	-0.046	1	gnomad	4	153258959	rs1490325931	T	C	gnomAD Exomes	p.Lys286Glu	c.856A>G
L288F	L	288	F	-0.908	59.843	0.132	6	gnomad	4	153258869	-	C	A	gnomAD Exomes	p.Leu288Phe	c.864G>T
A289S	A	289	S	-1.765	57.647	0.121	6	gnomad	4	153258868	rs1444335835	C	A	gnomAD Exomes	p.Ala289Ser	c.865G>T
Y291C	Y	291	C	-0.467	55.112	-0.254	2	gnomad	4	153258861	rs948405432	T	C	gnomAD Exomes	p.Tyr291Cys	c.872A>G
Y291N	Y	291	N	-0.601	55.112	-0.017	2	gnomad	4	153258862	rs369187069	A	T	gnomAD Exomes	p.Tyr291Asn	c.871T>A
K299E	K	299	E	0.02	40.936	0.004	1	gnomad	4	153258838	rs750051282	T	C	gnomAD Exomes	p.Lys299Glu	c.895A>G
L302I	L	302	I	-0.922	44.101	-0.084	1	gnomad	4	153258829	rs150506693	G	T	gnomAD Exomes	p.Leu302Ile	c.904C>A
T307I	T	307	I	-0.413	54.949	-0.006	1	gnomad	4	153258813	rs764174613	G	A	gnomAD Exomes	p.Thr307Ile	c.920C>T
R309H	R	309	H	-0.992	59.667	0.003	1	gnomad	4	153258807	rs760675122	C	T	gnomAD Exomes	p.Arg309His	c.926G>A
L319I	L	319	I	-0.533	49.037	-0.066	1	gnomad	4	153258778	rs1369661240	G	T	gnomAD Genomes	p.Leu319Ile	c.955C>A
K326R	K	326	R	-0.425	39.317	0.12	1	gnomad	4	153258756	rs773325030	T	C	gnomAD Exomes	p.Lys326Arg	c.977A>G
K326T	K	326	T	-0.52	39.317	-0.056	1	gnomad	4	153258756	rs773325030	T	G	gnomAD Exomes	p.Lys326Thr	c.977A>C
E327D	E	327	D	-0.513	37.333	0.1	1	gnomad	4	153258752	rs148769501	T	G	gnomAD Exomes	p.Glu327Asp	c.981A>C
G329E	G	329	E	-1.067	34.737	0.145	1	gnomad	4	153258720	rs1358178925	C	T	gnomAD Genomes	p.Gly329Glu	c.986G>A
I330V	I	330	V	-1.265	36.875	-0.056	1	gnomad	4	153258718	rs767438108	T	C	gnomAD Exomes	p.Ile330Val	c.988A>G
I336M	I	336	M	-0.569	45.102	0.19	1	gnomad	4	153251998	rs1046708929	G	C	gnomAD Exomes	p.Ile336Met	c.1008C>G
K337Q	K	337	Q	-0.295	47.538	0.194	1	gnomad	4	153251997	rs750480880	T	G	gnomAD Exomes	p.Lys337Gln	c.1009A>C
R338K	R	338	K	-0.216	50.737	0.251	3	gnomad	4	153251993	rs1185005670	C	T	gnomAD Exomes	p.Arg338Lys	c.1013G>A
V341A	V	341	A	-0.617	55.273	-0.144	1	gnomad	4	153251984	rs1485389861	A	G	gnomAD Exomes	p.Val341Ala	c.1022T>C
I342T	I	342	T	-0.67	57.24	-0.602	2	gnomad	4	153251981	rs765495879	A	G	gnomAD Exomes	p.Ile342Thr	c.1025T>G
I342V	I	342	V	-0.424	57.24	0.344	1	gnomad	4	153251982	rs1247097813	T	C	gnomAD Exomes	p.Ile342Val	c.1024A>G
I347V	I	347	V	-0.956	53.902	-0.016	1	gnomad	4	153251967	rs762013076	T	C	gnomAD Exomes	p.Ile347Val	c.1039A>G
H359R	H	359	R	-0.889	35.47	0.035	1	gnomad	4	153251930	rs1014611334	T	C	gnomAD Genomes	p.His359Arg	c.1076A>G
T363N	T	363	N	-1.29	31.186	-0.004	3	gnomad	4	153251918	rs1381320045	G	T	gnomAD Exomes	p.Thr363Asn	c.1088C>A
N364S	N	364	S	-1.14	29.412	-0.243	2	gnomad	4	153251915	rs775885576	T	C	gnomAD Exomes	p.Asn364Ser	c.1091A>G
R367Q	R	367	Q	-0.102	29.26	-0.019	7	gnomad	4	153251906	rs745418631	C	T	gnomAD Exomes,gnomAD Genomes	p.Arg367Gln	c.1100G>A
K371R	K	371	R	-0.371	27.686	0.115	1	gnomad	4	153251894	rs761747465	T	C	gnomAD Exomes	p.Lys371Arg	c.1112A>G
P373R	P	373	R	-0.297	23.003	-0.033	1	gnomad	4	153251888	rs748952220	G	C	gnomAD Exomes	p.Pro373Arg	c.1118C>G
K374E	K	374	E	0.473	21.263	-0.168	1	gnomad	4	153251886	rs937391131	T	C	gnomAD Exomes	p.Lys374Glu	c.1120A>G
L387V	L	387	V	-1.645	13.766	0.063	1	gnomad	4	153250901	rs1338105130	A	C	gnomAD Exomes	p.Leu387Val	c.1159T>G
S407L	S	407	L	-0.153	23.243	-0.1	1	gnomad	4	153250840	-	G	A	gnomAD Genomes	p.Ser407Leu	c.1220C>G
V418L	V	418	L	-0.209	15.903	-0.155	2	gnomad	4	153249526	rs755422880	C	A	gnomAD Exomes	p.Val418Leu	c.1252G>T
V418M	V	418	M	-0.517	15.903	-0.098	2	gnomad	4	153249526	rs755422880	C	T	gnomAD Exomes	p.Val418Met	c.1252G>A
N432I	N	432	I	0.078	26.504	-0.075	2	gnomad	4	153249483	rs772668762	T	A	gnomAD Exomes	p.Asn432Ile	c.1295A>T
I433F	I	433	F	-1.662	23.411	0.361	3	gnomad	4	153249481	rs761173677	T	A	gnomAD Exomes	p.Ile433Phe	c.1297A>T
I433V	I	433	V	-1.665	23.411	-0.172	2	gnomad	4	153249481	rs761173677	T	C	gnomAD Exomes	p.Ile433Val	c.1297A>G
I435V	I	435	V	-1.87	16.772	-0.377	1	gnomad	4	153249475	rs1190126709	T	C	gnomAD Exomes	p.Ile435Val	c.1303A>G
V445L	V	445	L	-0.729	18.426	-0.093	1	gnomad	4	153249445	rs776371212	C	A	gnomAD Exomes	p.Val445Leu	c.1333G>T
T456N	T	456	N	-0.895	14.647	-0.131	1	gnomad	4	153249411	rs775244232	G	T	gnomAD Exomes	p.Thr456Asn	c.1367C>A
L457F	L	457	F	-1.16	12.355	0.603	1	gnomad	4	153249407	rs1433184454	T	A	gnomAD Exomes	p.Leu457Phe	c.1371A>T
G459V	G	459	V	-0.347	9.584	-0.311	1	gnomad	4	153249402	rs772056210	C	A	gnomAD Exomes	p.Gly459Val	c.1376G>A
R465C	R	465*	C	-1.48	5.148	0.035	1	gnomad	4	153249385	rs867384286	G	A	gnomAD Exomes	p.Arg465Cys	c.1393C>T
E471G	E	471	G	-0.856	25.356	-0.243	12	gnomad	4	153249366	rs756238684	T	C	gnomAD Exomes	p.Glu471Gly	c.1412A>G
R479G	R	479*	G	-0.614	3.072	-1.265	1	gnomad	4	153247367	rs747241612	G	C	gnomAD Exomes	p.Arg479Gly	c.1435C>G
V485I	V	485	I	-1.163	17.029	-0.053	2	gnomad	4	153247349	rs1325363774	C	T	gnomAD Exomes	p.Val485Ile	c.1453G>A
I488T	I	488	T	-2.861	20.45	-0.025	1	gnomad	4	153247339	rs1222797439	A	G	gnomAD Exomes	p.Ile488Thr	c.1463T>C
H495R	H	495	R	-1.47	17.376	0.073	3	gnomad	4	153247318	rs750717620	T	C	gnomAD Exomes	p.His495Arg	c.1484A>G
Y509C	Y	509	C	-2.06	19.683	-0.627	2	gnomad	4	153247276	rs1334352027	T	C	gnomAD Exomes	p.Tyr509Cys	c.1526A>G
V515I	V	515	I	-0.697	16.152	-0.323	1	gnomad	4	153247259	rs757683191	C	T	gnomAD Exomes	p.Val515Ile	c.1543G>A
T532I	T	532	I	-0.371	20.341	-0.005	1	gnomad	4	153247207	rs1179476070	G	A	gnomAD Exomes	p.Thr532Ile	c.1595C>T
T541S	T	541	S	-0.708	6.634	0.083	1	gnomad	4	153247181	rs1184403966	T	A	gnomAD Exomes	p.Thr541Ser	c.1621A>T
N542S	N	542	S	-1.271	3.775	-0.02	1	gnomad	4	153247177	rs1462861861	T	C	gnomAD Exomes	p.Asn542Ser	c.1625A>G
R564C	R	564	C	-1.983	15.026	-0.448	1	gnomad	4	153245501	rs1024060344	G	A	gnomAD Genomes	p.Arg564Cys	c.1690C>T
T576M	T	576	M	0.072	16.356	-0.047	2	gnomad	4	153245464	rs1429385222	G	A	gnomAD Exomes	p.Thr576Met	c.1727C>T
M587I	M	587	I	-0.303	12.55	-0.345	1	gnomad	4	153245430	rs1269436440	C	T	gnomAD Exomes	p.Met587Ile	c.1761G>A
E588D	E	588	D	-1.234	15.447	0.029	2	gnomad	4	153245427	rs751435265	T	A	gnomAD Exomes	p.Glu588Asp	c.1764A>T
K590E	K	590	E	0.269	22.181	-0.234	1	gnomad	4	153245423	-	T	C	gnomAD Exomes	p.Lys590Glu	c.1768A>G
K590R	K	590	R	-0.309	22.181	-0.109	1	gnomad	4	153245422	rs1290448722	T	C			